Natural Terpenoids as Drug Candidates
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".
Deadline for manuscript submissions: closed (10 June 2024) | Viewed by 381
Special Issue Editors
Interests: natural products chemistry; mass spectrometry-based metabolomics; pharmacognosy
Special Issues, Collections and Topics in MDPI journals
Interests: natural products chemistry; marine natural products; aquaculture
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Terpenoids constitute the largest class of natural products, making them a rich source of potential candidates for new drug development. The name “terpenoids” comes from the fact that the first compound of this family was isolated from turpentine. The basic building block of this class of compounds is the “isoprene” unit, which is composed of five carbons. The combination of two isoprene units leads to the formation of “monoterpenes”, while the combination of three isoprene units leads to the formation of “sesquiterpenes” and the combination of four units results in the formation of “diterpenes”, and so on. Natural terpenoids can be isolated from different natural sources such as plants, animals, microbes, insects, plant pathogens and endophytes and marine organisms. Several reports including in vitro, preclinical and clinical studies have confirmed the wide array of important pharmacological properties of this class of compounds. Several compounds have been developed into drug leads including the anticancer drug Taxol® and the antimalarial drug artemisinin. It is a generally accepted fact among scientists that “Terpenes are the Next Frontiers in Wellness”. In the light of these successes, we are announcing this Special Issue to provide new insights into the potential of natural terpenoids as drug candidates. We aim to publish research manuscripts and reviews focusing on the following:
- The isolation of terpenoids from terrestrial plants, microbes, marine organisms and other sources;
- The development of new drug candidates from natural terpenoids;
- Pharmacokinetic and pharmacodynamic studies of drug candidates from natural terpenoids;
- The development of new analytical methods for the qualitative and quantitative determination of drug candidates from natural terpenoids;
- Evaluation of the pharmacological and toxicological effects of natural terpenoids;
- Evaluation of ADME of drug candidates from natural terpenoids;
- Clinical trials reporting the activities of drug candidates developed from natural terpenoids;
- The development of pharmaceutical preparations and new drug delivery systems of drug candidates from natural terpenoids;
- Evaluation of the biological targets and biomarkers of drug candidates from natural terpenoids including the determination of their target enzymes, receptors, membranes, genes, ion channels, inhibitors, agonists, antagonists, neurons and binding affinity;
- The application of computational methods for the development of drug candidates from natural terpenoids;
- The application of artificial intelligence for the development of drug candidates from natural terpenoids with optimum activity and minimum side effects;
- The application of biotechnological methods to produce natural terpenoids from different sources;
- The application of nanotechnology for the formulation of drug candidates from natural terpenoids.
Dr. Kuei-Hung Lai
Dr. Bo-Rong Peng
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
